REGNÂ – Regeneron Pharmaceuticals, Inc.
Float Short %
Margin Of Safety %
-2
Put/Call OI Ratio
0.61
EPS Next Q Diff
-1.86
EPS Last/This Y
2.28
EPS This/Next Y
-3.63
Price
755.54
Target Price
838.46
Analyst Recom
1.73
Performance Q
30.41
Relative Volume
0.76
Beta
0.4
Ticker: REGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | REGN | 784.33 | 0.48 | 1.21 | 51250 |
| 2025-12-29 | REGN | 780.59 | 0.49 | 0.83 | 50546 |
| 2025-12-30 | REGN | 774.73 | 0.49 | 1.31 | 51195 |
| 2025-12-31 | REGN | 772.15 | 0.50 | 1.70 | 51596 |
| 2026-01-02 | REGN | 776.48 | 0.51 | 1.46 | 52028 |
| 2026-01-05 | REGN | 764.23 | 0.50 | 1.79 | 50851 |
| 2026-01-06 | REGN | 776.32 | 0.53 | 0.74 | 51921 |
| 2026-01-07 | REGN | 812.9 | 0.53 | 0.52 | 52378 |
| 2026-01-08 | REGN | 801.06 | 0.54 | 0.83 | 53580 |
| 2026-01-09 | REGN | 796.24 | 0.54 | 1.70 | 54535 |
| 2026-01-12 | REGN | 766.5 | 0.57 | 1.45 | 55521 |
| 2026-01-13 | REGN | 758.58 | 0.58 | 1.05 | 56480 |
| 2026-01-14 | REGN | 754.53 | 0.59 | 3.06 | 56989 |
| 2026-01-15 | REGN | 741.57 | 0.59 | 2.48 | 57089 |
| 2026-01-16 | REGN | 732.85 | 0.58 | 1.13 | 57719 |
| 2026-01-20 | REGN | 733.97 | 0.61 | 1.67 | 42242 |
| 2026-01-21 | REGN | 749.27 | 0.61 | 0.81 | 42891 |
| 2026-01-22 | REGN | 755.44 | 0.61 | 0.60 | 43571 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | REGN | 784.19 | -11.3 | -1317.9 | 43.18 |
| 2025-12-29 | REGN | 780.72 | -11.3 | -1343.0 | 43.18 |
| 2025-12-30 | REGN | 774.62 | -11.3 | -1351.8 | 43.18 |
| 2025-12-31 | REGN | 771.86 | -11.3 | -1331.7 | 43.18 |
| 2026-01-02 | REGN | 776.51 | -11.3 | -1295.4 | 43.18 |
| 2026-01-05 | REGN | 763.20 | -11.3 | -1390.7 | 43.18 |
| 2026-01-06 | REGN | 776.37 | -11.3 | -1248.8 | 43.18 |
| 2026-01-07 | REGN | 812.91 | -11.3 | -1125.7 | 43.18 |
| 2026-01-08 | REGN | 801.01 | -11.3 | -1377.9 | 43.18 |
| 2026-01-09 | REGN | 796.38 | -11.5 | -1344.5 | 43.18 |
| 2026-01-12 | REGN | 768.01 | -11.5 | -1469.2 | 43.18 |
| 2026-01-13 | REGN | 758.58 | -12.8 | -1371.5 | 43.18 |
| 2026-01-14 | REGN | 754.26 | -12.8 | -1346.0 | 43.18 |
| 2026-01-15 | REGN | 741.92 | -12.3 | -1388.0 | 43.18 |
| 2026-01-16 | REGN | 733.04 | -12.3 | -1370.4 | 43.18 |
| 2026-01-20 | REGN | 733.78 | -12.3 | -1316.2 | 43.18 |
| 2026-01-21 | REGN | 749.33 | -12.3 | -1232.0 | 43.18 |
| 2026-01-22 | REGN | 755.54 | -12.0 | -1285.9 | 43.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-29 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-30 | REGN | -0.19 | -1.01 | 2.71 |
| 2025-12-31 | REGN | -0.19 | -1.01 | 2.71 |
| 2026-01-02 | REGN | -0.19 | -1.01 | 2.71 |
| 2026-01-05 | REGN | -0.19 | -0.99 | 2.71 |
| 2026-01-06 | REGN | -0.19 | -0.99 | 2.71 |
| 2026-01-07 | REGN | -0.19 | -0.99 | 2.71 |
| 2026-01-08 | REGN | -0.23 | -0.99 | 2.71 |
| 2026-01-09 | REGN | -0.23 | -0.99 | 2.71 |
| 2026-01-12 | REGN | -0.23 | -0.95 | 2.71 |
| 2026-01-13 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-14 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-15 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-16 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-20 | REGN | -0.23 | -1.17 | 2.46 |
| 2026-01-21 | REGN | -0.23 | -1.17 | 2.46 |
| 2026-01-22 | REGN | -0.23 | -1.17 | 0 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
11.83
Avg. EPS Est. Current Quarter
10.71
Avg. EPS Est. Next Quarter
9.96
Insider Transactions
-0.23
Institutional Transactions
-1.17
Beta
0.4
Average Sales Estimate Current Quarter
3758
Average Sales Estimate Next Quarter
3412
Fair Value
742.37
Quality Score
99
Growth Score
77
Sentiment Score
65
Actual DrawDown %
37.6
Max Drawdown 5-Year %
-59.7
Target Price
838.46
P/E
18.09
Forward P/E
16.78
PEG
3.13
P/S
5.57
P/B
2.57
P/Free Cash Flow
18.81
EPS
41.77
Average EPS Est. Cur. Y​
43.18
EPS Next Y. (Est.)
39.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.13
Relative Volume
0.76
Return on Equity vs Sector %
-12.5
Return on Equity vs Industry %
3.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
-1285.9
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15222
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading